| scholarly article | Q13442814 |
| P356 | DOI | 10.1200/JCO.2014.55.7348 |
| P698 | PubMed publication ID | 25225436 |
| P50 | author | Isabelle Ray-Coquard | Q37995869 |
| Jae-Weon Kim | Q40344066 | ||
| Eric Pujade-Lauraine | Q40944740 | ||
| Carmen Schade-Brittinger | Q47499182 | ||
| Sandro Pignata | Q56419526 | ||
| Muneaki Shimada | Q88144741 | ||
| Ignace Vergote | Q89808263 | ||
| Giovanni Scambia | Q91909477 | ||
| Keiichi Fujiwara | Q92525856 | ||
| Bradley J. Monk | Q107013145 | ||
| P2093 | author name string | Michael Friedlander | |
| Qiong Wang | |||
| Andreas du Bois | |||
| Christian Kurzeder | |||
| Philipp Harter | |||
| Jae-Hoon Kim | |||
| Nicoletta Colombo | |||
| Thomas J Herzog | |||
| Byoung-Gie Kim | |||
| Christian Marth | |||
| Paul Vasey | |||
| Rongyu Zang | |||
| Marie-Ange Mouret-Reynier | |||
| Ulrich Canzler | |||
| Rainer Kimmig | |||
| Mansoor R Mirza | |||
| Ivan Diaz-Padilla | |||
| Ionel Mitrica | |||
| Rocco Crescenzo | |||
| Anne Floquet | |||
| Paula Calvert | |||
| Joern Rau | |||
| Anne Lesoin | |||
| Klaus H Baumann | |||
| Josep M del Campo | |||
| P433 | issue | 30 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | ovarian cancer | Q172341 |
| P304 | page(s) | 3374-3382 | |
| P577 | publication date | 2014-09-15 | |
| P1433 | published in | Journal of Clinical Oncology | Q400292 |
| P1476 | title | Incorporation of pazopanib in maintenance therapy of ovarian cancer | |
| P478 | volume | 32 |
| Q55064836 | A Phase I, Dose-Escalation Trial of Pazopanib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A UNICANCER Study. |
| Q58712023 | A new promising way of maintenance therapy in advanced ovarian cancer: a comparative clinical study |
| Q43902249 | A phase 2 study of cediranib in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: a trial of the Princess Margaret, Chicago and California Phase II Consortia |
| Q91567056 | A randomized phase II evaluation of weekly gemcitabine plus pazopanib versus weekly gemcitabine alone in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma |
| Q99635825 | A real-world study on characteristics, treatments and outcomes in US patients with advanced stage ovarian cancer |
| Q38644521 | A review of HER2-targeted therapy in breast and ovarian cancer: lessons from antiquity - CLEOPATRA and PENELOPE. |
| Q89094825 | Addition of intraperitoneal cisplatin and etoposide to first-line chemotherapy for advanced ovarian cancer: a randomised, phase 2 trial |
| Q48104995 | Advances in ovarian cancer therapy |
| Q38553247 | An overview of early investigational therapies for chemoresistant ovarian cancer. |
| Q38631373 | An overview of tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer. |
| Q38881168 | An update on current and emerging therapies for epithelial ovarian cancer: Focus on poly(adenosine diphosphate-ribose) polymerase inhibition and antiangiogenesis. |
| Q55217694 | Angiogenesis Inhibitors for the Treatment of Ovarian Cancer: An Updated Systematic Review and Meta-analysis of Randomized Controlled Trials. |
| Q38872239 | Anti-angiogenic agents in ovarian cancer: past, present, and future. |
| Q58706801 | Antiangiogenesis therapy in ovarian cancer patients: An updated meta-analysis for 15 randomized controlled trials |
| Q33572395 | Antiangiogenic Treatment in Ovarian Cancer in the Era of Evidenced-Based Medicine |
| Q28073722 | Antiangiogenic therapies in ovarian cancer |
| Q90783657 | Apatinib combined with oral etoposide in patients with platinum-resistant or platinum-refractory ovarian cancer (AEROC): a phase 2, single-arm, prospective study |
| Q92548235 | Assessment of Progression-Free Survival as a Surrogate End Point of Overall Survival in First-Line Treatment of Ovarian Cancer: A Systematic Review and Meta-analysis |
| Q27853316 | BRCA1/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study. |
| Q38822258 | Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial |
| Q92035335 | Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial |
| Q90377414 | Bevacizumab combined with platinum-taxane chemotherapy as first-line treatment for advanced ovarian cancer: a prospective observational study of safety and efficacy in Japanese patients (JGOG3022 trial) |
| Q98158111 | Bevacizumab plus fosbretabulin in recurrent ovarian cancer: Overall survival and exploratory analyses of a randomized phase II NRG oncology/gynecologic oncology group study |
| Q26779120 | Beyond Bevacizumab: An Outlook to New Anti-Angiogenics for the Treatment of Ovarian Cancer |
| Q35669792 | CECs and IL-8 Have Prognostic and Predictive Utility in Patients with Recurrent Platinum-Sensitive Ovarian Cancer: Biomarker Correlates from the Randomized Phase-2 Trial of Olaparib and Cediranib Compared with Olaparib in Recurrent Platinum-Sensitiv |
| Q34520190 | Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial. |
| Q34514973 | Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer |
| Q36122605 | Cellular and molecular processes in ovarian cancer metastasis. A Review in the Theme: Cell and Molecular Processes in Cancer Metastasis |
| Q38434094 | Characterisation of liver chemistry abnormalities associated with pazopanib monotherapy: a systematic review and meta-analysis of clinical trials in advanced cancer patients |
| Q26771397 | Chemotherapy of ovarian cancer in elderly patients |
| Q38968504 | Clinical Pharmacokinetics and Pharmacodynamics of Pazopanib: Towards Optimized Dosing |
| Q38936104 | Clinical pharmacology, drug-drug interactions and safety of pazopanib: a review |
| Q36171560 | Communicating BRCA research results to patients enrolled in international clinical trials: lessons learnt from the AGO-OVAR 16 study |
| Q92697428 | Comparative efficacy of targeted maintenance therapy for newly diagnosed epithelial ovarian cancer: a network meta-analysis |
| Q90736221 | Comparing Paclitaxel-Carboplatin with Paclitaxel-Cisplatin as the Front-Line Chemotherapy for Patients with FIGO IIIC Serous-Type Tubo-Ovarian Cancer |
| Q37376481 | Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experience |
| Q38751236 | Current and emerging treatment options in the management of advanced ovarian cancer |
| Q37158437 | Evaluation of rucaparib and companion diagnostics in the PARP inhibitor landscape for recurrent ovarian cancer therapy |
| Q38874036 | FIGO stage IV epithelial ovarian, fallopian tube and peritoneal cancer revisited |
| Q40613027 | Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): Long-term survival, impact of ascites, and progression-free survival-2. |
| Q52584387 | First-line treatment of ovarian cancer: questions and controversies to address. |
| Q49895978 | Front-line therapy of advanced epithelial ovarian cancer: standard treatment |
| Q47323988 | Front-line therapy of advanced ovarian cancer: new approaches |
| Q38669746 | Frontline treatment of epithelial ovarian cancer. |
| Q38818448 | Gene therapy for ovarian cancer using carbonyl reductase 1 DNA with a polyamidoamine dendrimer in mouse models |
| Q57173042 | Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised |
| Q64111448 | High-Grade Serous Ovarian Cancer: Basic Sciences, Clinical and Therapeutic Standpoints |
| Q50420907 | Impact of Phosphoproteomics in the Era of Precision Medicine for Prostate Cancer |
| Q28079328 | Incidence and risk of hypertension associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a comprehensive network meta-analysis of 72 randomized controlled trials involving 30013 patients |
| Q47146356 | Increased PDGFR-beta and VEGFR-2 protein levels are associated with resistance to platinum-based chemotherapy and adverse outcome of ovarian cancer patients. |
| Q99592076 | Integrative network analysis identifies potential targets and drugs for ovarian cancer |
| Q58110912 | International Gynecologic Cancer Society (IGCS) 2018: Meeting report |
| Q38340008 | Investigational therapies currently in Phase II clinical trials for the treatment of pelvic serous carcinomas. |
| Q90231859 | Kinase Inhibitors and Ovarian Cancer |
| Q26781561 | Maintenance Therapy in Ovarian Cancer with Targeted Agents Improves PFS and OS: A Systematic Review and Meta-Analysis |
| Q24201758 | Maintenance chemotherapy for ovarian cancer |
| Q91592202 | Maintenance of pegylated liposomal doxorubicin/carboplatin in patients with advanced ovarian cancer: randomized study of an Asian Gynecologic Oncology Group |
| Q26992183 | Major clinical research advances in gynecologic cancer in 2014 |
| Q26741755 | Management of relapsed ovarian cancer: a review |
| Q50209212 | Management of the toxicities of common targeted therapeutics for gynecologic cancers |
| Q38824319 | Molecular imaging in ovarian cancer. |
| Q26781662 | More than a Decade of Tyrosine Kinase Inhibitors in the Treatment of Solid Tumors: What We Have Learned and What the Future Holds |
| Q54939123 | Multiline treatment combining apatinib with toptecan for platinum-resistant recurrent ovarian cancer patients: a report of three cases. |
| Q42347314 | Negative trials in ovarian cancer: is there such a thing as too much optimism? |
| Q53981393 | Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio before chemotherapy as potential prognostic factors in patients with newly diagnosed epithelial ovarian cancer. |
| Q28082524 | New perspectives on targeted therapy in ovarian cancer |
| Q51824301 | Nintedanib in ovarian cancer. |
| Q57064748 | Oncobox Bioinformatical Platform for Selecting Potentially Effective Combinations of Target Cancer Drugs Using High-Throughput Gene Expression Data |
| Q89672121 | Oral metronomic chemotherapy for recurrent & refractory epithelial ovarian cancer: A retrospective analysis |
| Q26777846 | Ovarian Cancer Molecular Stratification and Tumor Heterogeneity: A Necessity and a Challenge |
| Q88195269 | Ovarian cancer |
| Q26862249 | Ovarian cancer standard of care: are there real alternatives? |
| Q37713683 | Ovarian cancer stem cells: still an elusive entity? |
| Q36554444 | Ovarian cancer treatment: The end of empiricism? |
| Q90098861 | Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer |
| Q40611979 | PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis |
| Q47306372 | Paclitaxel With and Without Pazopanib for Persistent or Recurrent Ovarian Cancer: A Randomized Clinical Trial |
| Q36811358 | Patients with Advanced Ovarian Cancer Administered Oral Etoposide following Taxane as Maintenance Chemotherapy |
| Q52867263 | Pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant, recurrent, pre-treated ovarian cancer - Results of the PACOVAR-trial. |
| Q89370037 | Pazopanib Monotherapy Is Active in Relapsed and Refractory Metastatic Gastroesophageal Adenocarcinoma and Can Produce Durable Response |
| Q37512369 | Pazopanib as a second line treatment for uterine and ovarian carcinosarcoma: a single institutional study |
| Q38571120 | Pazopanib in ovarian cancer |
| Q26746205 | Pazopanib in the management of advanced soft tissue sarcomas |
| Q47642693 | Pazopanib maintenance after first-line etoposide and platinum chemotherapy in patients with extensive disease small-cell lung cancer: a multicentre, randomised, placebo-controlled Phase II study (KCSG-LU12-07). |
| Q50564383 | Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial. |
| Q55419813 | Pazopanib treatment of a platinum-resistant recurrence of a high-grade Sertoli cell tumor and assessment of the treatment response by FDG-PET/CT: A case report. |
| Q27024948 | Perioperative and Maintenance Therapy After First-Line Therapy as Paradigms for Drug Discovery in Urothelial Carcinoma |
| Q37570010 | Platelet Derived Growth Factor BB: A "Must-have" Therapeutic Target "Redivivus" in Ovarian Cancer. |
| Q36730777 | Prediction of anti-angiogenesis escape |
| Q39263260 | Prediction of therapy response in ovarian cancer: Where are we now? |
| Q53343236 | Preoperative Treatment With Pazopanib in a Case of Chemotherapy-Resistant Infantile Fibrosarcoma. |
| Q57493808 | Prognostic impact of high c-Met expression in ovarian cancer: a meta-analysis |
| Q37024702 | Progression-free and overall survival in ovarian cancer patients treated with CVac, a mucin 1 dendritic cell therapy in a randomized phase 2 trial |
| Q38272779 | Progression-free survival by local investigator versus independent central review: comparative analysis of the AGO-OVAR16 Trial |
| Q36143478 | Risk factors for pneumothorax in advanced and/or metastatic soft tissue sarcoma patients during pazopanib treatment: a single-institute analysis |
| Q31125419 | Same Data; Different Interpretations |
| Q57052684 | Secondary spontaneous pneumothorax in patients with sarcoma treated with Pazopanib, a case control study |
| Q56957787 | Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer (TRIAS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial |
| Q33427744 | Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial |
| Q85579065 | State of the science: Emerging therapeutic strategies for targeting angiogenesis in ovarian cancer |
| Q100761888 | Synthesis, in vitro, and in vivo evaluation of novel N-phenylindazolyl diarylureas as potential anti-cancer agents |
| Q58753938 | Systematic bias between blinded independent central review and local assessment: literature review and analyses of 76 phase III randomised controlled trials in 45 688 patients with advanced solid tumour |
| Q64058293 | Tailoring Ovarian Cancer Treatment: Implications of Mutations |
| Q47685928 | Targeted Therapies in the Management of Ovarian Cancer: A Focus on Older Patients |
| Q38760610 | Targeted agents and combinations in ovarian cancer: where are we now? |
| Q26750649 | Targeted agents in epithelial ovarian cancer: review on emerging therapies and future developments |
| Q98164379 | Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence |
| Q55438200 | Targeted therapy and immunotherapy for platinum-refractory advanced ovarian adenosquamous carcinoma: a case report. |
| Q63359576 | Targeted therapy in ovarian cancer |
| Q41607677 | Targeted therapy of ovarian cancer including immune check point inhibitor |
| Q38802077 | Targeting the hallmarks of ovarian cancer: The big picture |
| Q36626921 | Targeting the tumour microenvironment in ovarian cancer |
| Q41619260 | Thalidomide and lenalidomide for recurrent ovarian cancer: A systematic review of the literature |
| Q30248645 | The Emerging Role of Tyrosine Kinase Inhibitors in Ovarian Cancer Treatment: A Systematic Review |
| Q38715211 | The Role of the Immune System in Ovarian Cancer and Implications on Therapy |
| Q53224409 | The clinical value of surgeons' efforts of preventing intraoperative tumor rupture in stage I clear cell carcinoma of the ovary: A Korean multicenter study. |
| Q39151484 | The development and use of vascular targeted therapy in ovarian cancer |
| Q92587632 | The management of malignant ascites and impact on quality of life outcomes in women with ovarian cancer |
| Q35920527 | The prognostic significance of anti-angiogenesis therapy in ovarian cancer: a meta-analysis |
| Q50345037 | The rise of genomic profiling in ovarian cancer |
| Q49966031 | The role of Cediranib in ovarian cancer |
| Q61818032 | Therapeutic advances in hormone-dependent cancers: focus on prostate, breast and ovarian cancers |
| Q64109213 | Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial |
| Q98771756 | Tumor Microenvironment in Ovarian Cancer: Function and Therapeutic Strategy |
| Q91645432 | Weekly Dose-Dense Paclitaxel and Triweekly Low-Dose Cisplatin: A Well-Tolerated and Effective Chemotherapeutic Regimen for First-Line Treatment of Advanced Ovarian, Fallopian Tube, and Primary Peritoneal Cancer |
Search more.